Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...
In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot. Reading time 3 minutes Next-generation vaccines could make the flu season ...
Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. Of 9,225 ...
Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported. The Pfizer flu vaccine uses the same type of messenger RNA science that was used in the ...
Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported. The results, published Nov. 19 in The New England Journal of Medicine, suggest that ...
BioNTech co-founders Dr. Ugur Sahin and Dr. Ozlem Tureci in its headquarters in Germany on Jan. 3.Photograph by Dina Litovsky—Redux for TIME “No!” The doctor snapped. “Look at me!” I had been staring ...
Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. Subscribe to read this story ...
Pfizer’s mRNA flu shot prevented more flu-like illness than a standard vaccine More than 18,000 adults took part in the study Side effects were mild and went away quickly FRIDAY, Nov. 21, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results